Publicaciones en las que colabora con Ángela Gutiérrez Camino (30)

2020

  1. Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia

    Epigenomics, Vol. 12, Núm. 22, pp. 1949-1955

2019

  1. MiRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review

    Epigenomics, Vol. 12, Núm. 1, pp. 69-80

  2. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 19, Núm. 6, pp. 564-569

2018

  1. Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk

    Oncotarget, Vol. 9, Núm. 33, pp. 22907-22914

  2. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment

    Pharmacogenomics, Vol. 19, Núm. 18, pp. 1403-1412

  3. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 18, Núm. 6, pp. 704-712

  4. Osteosarkoma pediatrikoarekiko suszeptibilitatean inplikatuta dauden aldaera genetikoak

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 34, pp. 59-82

  5. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity

    Epigenomics, Vol. 10, Núm. 4, pp. 409-417

  6. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 19, Núm. 4, pp. 361-373

  7. Variants in the 14q32 miRNA cluster are associated with osteosarcoma risk in the Spanish population

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population

    PLoS ONE, Vol. 12, Núm. 5

  2. Genetic susceptibility in childhood acute lymphoblastic leukemia

    Medical Oncology, Vol. 34, Núm. 10

  3. MTHFR polymorphisms in childhood acute lymphoblastic leukemia: Influence on methotrexate therapy

    Pharmacogenomics and Personalized Medicine, Vol. 10, pp. 69-78

  4. PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort

    Clinical Pharmacology and Therapeutics

  5. Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene

    Drug Metabolism and Personalized Therapy, Vol. 32, Núm. 1, pp. 1-9

  6. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia

    Pharmacogenetics and Genomics, Vol. 27, Núm. 8, pp. 303-306

2016

  1. Lack of association of the CEP72 RS924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population

    Pharmacogenetics and Genomics, Vol. 26, Núm. 2, pp. 100-102

  2. MIR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenetics and Genomics, Vol. 26, Núm. 11, pp. 517-525

  3. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 17, Núm. 7, pp. 731-741

2015

  1. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 15, Núm. 3, pp. 248-254